Clinical Trial Search

Primary: Ischemia Area at Risk as Determined by Paired Single-photon Computed Tomography Studies With Technetium Tc99m Sestamibi.

Primary: Global Infarct Size — 5.453; 8.598; 9.004; 7.819 Percentage of global infarct size

Primary: Primary Endpoint - Infarct Size at 30 Days as a Percentage of Total Left Ventricular Mass - Abciximab Infusion vs. No Infusion — 15.1; 17.9; 17.2 Percentage of Left…

Primary: C Reactive Protein (Area Under the Curve) — 75.9 mg/L

Primary: Cardiac Death — 0; 0 events

Primary: Arrhythmias of Interest, 48 Hours (Overall) — 0; 0; 0; 0 participants

Primary: Difference in Flow-mediated Dilation in the Brachial Artery in the Base and After the Treatment. — 11.24; 7.70 percent change dilatation — p=0.05

Primary: The Sensitivity and Specificity of ECG for Acute Coronary Occlusion. — 767; 282; 16 Participants

Primary: Progression of Acute Coronary Syndrome to Myocardial Infarction — 200; 242 participants — p=0.28

Primary: Index of Microcirculatory Resistance — 24.8; 45.0 units

Primary: Changes of Nt-proBNP (N-terminales Pro Brain Natriuretic Peptide) Levels — -84.9; -82.2 pg/mL

Primary: Number of Patients With ST-segment Elevation Resolution Equal or More Than 50% — 47; 51 participants — p=0.56

Primary: Composite of: Cardiovascular Death*, Re-myocardial Infarct, Re-hospitalization for Heart Failure (HF) and Congestive Heart Failure (CHF), Resuscitation or ICD…

Primary: Change From Baseline to Day 253 in Non-calcified Plaque Volume in the Most Diseased Coronary Segment (NCPVMD), as Measured by Computed Tomography Angiography (CTA)…

Primary: Left Ventricular Ejection Fraction Assessed by Cardiac Magnetic Resonance Imaging (CMRI) — 5.6; 5.3; 5.7 percentage of left ventricular volumes

Primary: Difference Between the Anakinra Arm and the Placebo Arm in Change in Left Ventricular End-systolic Volume Indices — 1.5; 1.0 mL/m2 — p=<0.05

Primary: Area Under the Curve (AUC) of Serum Creatine Kinase Isoenzyme Type Muscle-brain (CK-MB) — 6582.0; 6738.3; 5252.2; 5471.9 ng*hr/mL

Primary: Adjusted Mean Monthly Percent of Days Covered With B-blocker Following Intervention Date — 66.37; 70.62 Adjusted monthly % of days covered

Primary: Number of Participants With Any Adverse Events (AEs) and Serious Adverse Events (SAEs) — 97; 138; 131; 269 Participants

Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 28; 30; 31; 14 Participants

Primary: Number of Death — 417; 137; 552 Participants

Primary: Percent of Participants With at Least One Occurrence of Treatment-emergent Renal Serious Adverse Events (SAEs) (SAF) — 1.9; 14.3 percentage of participants

Primary: High-Sensitivity Cardiac Troponin Levels From Days 0-7 — 29.2; 17.3; 23.2; 16.7 ng/mL (0-0.04) — p=0.05

Primary: Infarct Size on Baseline Cardiac Magnetic Resonance Imaging (cMRI) — 20.1; 21.0 ml — p=0.90

Primary: Myeloperoxidase — 184.3; 66.5; 144.71 g/L

Primary: Change in Left Ventricular End Diastolic Volume (LVEDV) — 16.4; 15.8 mL

Primary: Number of Major Adverse Cardiac Events (MACE) — 9; 6; 2; 119 Participants

Primary: Number of Participants With All-cause Mortality or Nonfatal Myocardial Reinfarction — 255; 295 Participants

Primary: Improvement in Left Ventricular Ejection Fraction — 53.1; 54.8 % of LVEF

Primary: Number of Participants Readmitted Within 30-days Post Hospital Discharge — 13; 145 Participants — p=0.018